ReviewInternal medicine journal2026
Alcohol use disorder: an Australian perspective on screening, diagnosis, treatment and prevention.
Review in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol is one of Australia's most harmful recreational drugs, contributing more to death, disease and economic harm than all illicit drugs combined. Though it accounts for 4.1% of the national disease burden, it remains under-prioritised in health policy, prevention and treatment. Most of this harm is downstream of hazardous alcohol consumption and untreated alcohol use disorder (AUD), a common but stigmatised condition that is under-recognised and rarely treated with evidence-based therapies. Alcohol-related harm falls disproportionately on First Nations peoples, rural communities and socioeconomically disadvantaged Australians. Epidemiological trends are alarming: hospitalisations for alcohol-related liver disease are rising, and emerging data show a causal link between alcohol and early-onset colorectal cancer. These findings underscore alcohol's role as both a hepatotoxin and a multisystem carcinogen, with harms manifesting at younger ages and lower levels of consumption than previously recognised. Despite clear evidence that no level of alcohol use is safe, misconceptions persist, fuelled by industry influence and inconsistent public health messaging. Evidence-based treatments exist but are underused: only 2.9% of Australians with AUD receive approved pharmacotherapy, and delays to treatment average 18 years. Population-level strategies such as taxation, pricing and marketing restrictions remain the most effective levers, but progress is weak, as illustrated by the repeal of minimum unit pricing in the Northern Territory. Clinicians play a central role in reframing hazardous drinking and AUD as the root cause of alcohol-related disease and in advocating for evidence-based, patient-centred care and policy. Addressing AUD directly offers the clearest path to reducing Australia's alcohol burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.